Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Camp4 Therapeutics (CAMP) EBITDA Margin: 2023-2025

Historic EBITDA Margin for Camp4 Therapeutics (CAMP) over the last 1 years, with Sep 2025 value amounting to -1,899.25%.

  • Camp4 Therapeutics' EBITDA Margin fell 2364763.00% to -1,899.25% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,404.47%, marking a year-over-year change of. This contributed to the annual value of -7,943.40% for FY2024, which is 613974.00% up from last year.
  • According to the latest figures from Q3 2025, Camp4 Therapeutics' EBITDA Margin is -1,899.25%, which was down 125.88% from -840.81% recorded in Q2 2025.
  • Camp4 Therapeutics' 5-year EBITDA Margin high stood at 21,748.39% for Q3 2024, and its period low was -3,341.71% during Q3 2023.
  • Over the past 3 years, Camp4 Therapeutics' median EBITDA Margin value was -1,449.07% (recorded in 2025), while the average stood at 3,975.93%.
  • As far as peak fluctuations go, Camp4 Therapeutics' EBITDA Margin soared by 2,509,010bps in 2024, and later crashed by 2,364,763bps in 2025.
  • Over the past 3 years, Camp4 Therapeutics' EBITDA Margin (Quarterly) stood at 15,650.60% in 2023, then tumbled by 1,768,726bps to -2,036.66% in 2024, then crashed by 2,364,763bps to -1,899.25% in 2025.
  • Its last three reported values are -1,899.25% in Q3 2025, -840.81% for Q2 2025, and -1,449.07% during Q1 2025.